What is the share price of Indegene Ltd (INDGN) today?
The share price of INDGN as on 5th May 2026 is ₹544.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Indegene Ltd (INDGN) share?
The past returns of Indegene Ltd (INDGN) share are- Past 1 week: 9.26%
- Past 1 month: 17.26%
- Past 3 months: 13.27%
- Past 6 months: 2.71%
- Past 1 year: -2.34%
- Past 3 years: N/A%
- Past 5 years: -4.62%
What are the peers or stocks similar to Indegene Ltd (INDGN)?
The peers or stocks similar to Indegene Ltd (INDGN) include:What is the dividend yield % of Indegene Ltd (INDGN) share?
The current dividend yield of Indegene Ltd (INDGN) is 0.41.What is the market cap of Indegene Ltd (INDGN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Indegene Ltd (INDGN) is ₹13117.08 Cr as of 5th May 2026.What is the 52 week high and low of Indegene Ltd (INDGN) share?
The 52-week high of Indegene Ltd (INDGN) is ₹632.90 and the 52-week low is ₹414.What is the PE and PB ratio of Indegene Ltd (INDGN) stock?
The P/E (price-to-earnings) ratio of Indegene Ltd (INDGN) is 32.70. The P/B (price-to-book) ratio is 5.01.Which sector does Indegene Ltd (INDGN) belong to?
Indegene Ltd (INDGN) belongs to the Industrials sector & Business Support Services sub-sector.How to buy Indegene Ltd (INDGN) shares?
You can directly buy Indegene Ltd (INDGN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Indegene Ltd
INDGN Share Price
NSE₹544.502.09% (+11.15)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
INDGN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is underpriced but is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
INDGN Performance & Key Metrics
INDGN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 32.70 | 5.01 | 0.41% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 42.75 | 6.82 | 0.60% |
71%
Analysts have suggested that investors can buy this stock
from 7 analysts
Price Upside
Earnings Growth
Rev. Growth
INDGN Company Profile
Indegene Limited is a life sciences commercialization company. It provides digital-led commercialization services for the life sciences industry.
KFINTECH
PE Ratio
45.00
45.00
1Y Return
17.60%
17.60%
Buy Reco %
84.21
84.21
RITES
PE Ratio
28.25
28.25
1Y Return
0.71%
0.71%
Buy Reco %
50.00
50.00
SIS
PE Ratio
41.23
41.23
1Y Return
23.59%
23.59%
Buy Reco %
100.00
100.00
ARTEMISMED
PE Ratio
48.32
48.32
1Y Return
3.48%
3.48%
Buy Reco %
66.67
66.67
SANGHVIMOV
PE Ratio
17.60
17.60
1Y Return
17.64%
17.64%
Buy Reco %
0.00
0.00
INDGN Sentiment Analysis
INDGN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
INDGN Stock Summary · February 2026
Indegene demonstrated robust financial momentum with a remarkable 30.8% year-on-year revenue growth, driven by strategic investments in technology and a strong client base expansion. Despite facing challenges from increased amortization and operational costs, management remains optimistic about future profitability, anticipating integration synergies from the BioPharm acquisition to enhance earnings. The company is effectively leveraging Generative AI to streamline operations and improve client engagement, positioning itself favorably in a competitive market. Additionally, stable contract renewals and proactive client strategies are expected to convert short-term projects into recurring revenue streams, further solidifying Indegene's growth trajectory. Overall, the focus on innovation and operational excellence underpins a positive outlook for the upcoming quarters.
INDGN Stock Growth Drivers
INDGN Stock Growth Drivers
8Strong Financial Performance
Indegene Limited reported impressive financial results for Q3 FY26, achieving a revenue growth of 30.8%
Successful Client Engagements and Contracts
Indegene secured several significant contracts in the current quarter, including seven large deals exceeding $1
INDGN Stock Challenges
INDGN Stock Challenges
4Impact of Recent Investments on Profitability
The company has faced significant challenges due to planned investments aimed at enhancing go-to-market capabilities
Decline in Profit After Tax (PAT) and Margins
The Profit After Tax (PAT) for the quarter was INR1,026 million, showing a 0.5% sequential
INDGN Forecast
INDGN Forecasts
Price
Revenue
Earnings
INDGN Share Price Forecast
INDGN Share Price Forecast
2026
Current
₹544.50
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹544.50
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
INDGN Company Revenue Forecast
INDGN Company Revenue Forecast
2026
Current
₹3.58
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹3.58
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
INDGN Stock EPS (Earnings Per Share) Forecast
INDGN Stock EPS (Earnings Per Share) Forecast
2026
Current
₹16.72
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹16.72
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
INDGN
INDGN
Income
Balance Sheet
Cash Flow
Quarterly Normal View
INDGN Income Statement
INDGN Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 686.50 | 698.60 | 699.00 | 708.20 | 758.10 | 781.20 | 782.90 | 823.90 | 961.50 | 1,014.20 | ||||||||||
Operating & Other expenses | 524.50 | 534.30 | 547.60 | 560.70 | 588.60 | 608.10 | 605.50 | 663.60 | 782.60 | 860.10 | ||||||||||
EBITDA | 162.00 | 164.30 | 151.40 | 147.50 | 169.50 | 173.10 | 177.40 | 160.30 | 178.90 | 154.10 | ||||||||||
| Depreciation/Amortization | 17.60 | 18.50 | 20.10 | 19.40 | 20.00 | 20.70 | 21.60 | 23.40 | 39.60 | 41.80 | ||||||||||
| PBIT | 144.40 | 145.80 | 131.30 | 128.10 | 149.50 | 152.40 | 155.80 | 136.90 | 139.30 | 112.30 | ||||||||||
| Interest & Other Items | 12.10 | 12.30 | 11.70 | 4.00 | 3.20 | 3.10 | 3.70 | 3.80 | 4.60 | 7.20 | ||||||||||
| PBT | 132.30 | 133.50 | 119.60 | 124.10 | 146.30 | 149.30 | 152.10 | 133.10 | 134.70 | 105.10 | ||||||||||
| Taxes & Other Items | 33.50 | 38.70 | 31.90 | 32.40 | 36.60 | 31.70 | 35.70 | 31.00 | 31.80 | 25.40 | ||||||||||
| Net Income | 98.80 | 94.80 | 87.70 | 91.70 | 109.70 | 117.60 | 116.40 | 102.10 | 102.90 | 79.70 | ||||||||||
| EPS | 4.45 | 4.27 | 3.79 | 3.84 | 4.59 | 4.91 | 4.86 | 4.26 | 4.29 | 3.32 |
INDGN Company Updates
FY 2026FY 2026
Investor Presentation
Oct 2PDF
INDGN Stock Peers
INDGN Past Performance & Peer Comparison
INDGN Past Performance & Peer Comparison
Comparing 3 stocks from
IndustrialsBusiness Support Services
Compare valuation on Screener
IndustrialsBusiness Support Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Indegene Ltd | 32.70 | 5.01 | 0.41% |
| Kfin Technologies Ltd | 45.00 | 10.99 | 1.34% |
| RITES Ltd | 28.25 | 3.95 | 3.34% |
| SIS Ltd | 41.23 | 2.36 | — |
INDGN Stock Price Comparison
Compare INDGN with any stock or ETFCompare INDGN with any stock or ETF
INDGN
INDGN Holdings
INDGN Shareholdings
INDGN Promoter Holdings Trend
INDGN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
INDGN Institutional Holdings Trend
INDGN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.22%
INDGN Shareholding Pattern
INDGN Shareholding Pattern
INDGN Shareholding History
INDGN Shareholding History
Foreign Institutions
Mutual Funds Invested in INDGN
Mutual Funds Invested in INDGN
No mutual funds holding trends are available
Top 5 Mutual Funds holding Indegene Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7065% | Percentage of the fund’s portfolio invested in the stock 2.02% | Change in the portfolio weight of the stock over the last 3 months 0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/42 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6308% | Percentage of the fund’s portfolio invested in the stock 0.64% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/79 (+14) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5301% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 75/85 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing INDGN stock
smallcases containing INDGN stock
Looks like this stock is not in any smallcase yet.
INDGN Events
INDGN Events
INDGN Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
INDGN Dividend Trend
No dividend trend available
INDGN Upcoming Dividends
INDGN Upcoming Dividends
No upcoming dividends are available
INDGN Past Dividends
INDGN Past Dividends
Cash Dividend
Ex DateEx DateJun 13, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 13, 2025
INDGN Stock News & Opinions
INDGN Stock News & Opinions
Articles & Videos
Corporate
Board of Indegene recommends final dividend
Indegene announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 2.25 per equity Share (i.e. 112.5%) , subject to the approval of the shareholders.
5 days agoCapital Market - Live
Earnings
Indegene consolidated net profit declines 32.23% in the March 2026 quarter
Net profit of Indegene declined 32.23% to Rs 79.70 crore in the quarter ended March 2026 as against Rs 117.60 crore during the previous quarter ended March 2025. Sales rose 32.80% to Rs 1003.40 crore in the quarter ended March 2026 as against Rs 755.60 crore during the previous quarter ended March 2025. For the full year,net profit declined 1.38% to Rs 401.10 crore in the year ended March 2026 as against Rs 406.70 crore during the previous year ended March 2025. Sales rose 23.64% to Rs 3510.50 crore in the year ended March 2026 as against Rs 2839.30 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1003.40755.60 33 3510.502839.30 24 OPM %16.3019.52 -17.6318.82 - PBDT167.20170.00 -2 671.70619.50 8 PBT125.40149.30 -16 545.30539.30 1 NP79.70117.60 -32 401.10406.70 -1 Powered by Capital Market - Live
5 days agoCapital Market - Live
Corporate
Indegene to table results
Indegene will hold a meeting of the Board of Directors of the Company on 29 April 2026.
1 week agoCapital Market - Live
Spotlight
Volumes spurt at Indegene Ltd counter
APL Apollo Tubes Ltd, Elgi Equipments Ltd, Kirloskar Oil Engines Ltd, AAVAS Financiers Ltd are among the other stocks to see a surge in volumes on BSE today, 12 February 2026.Indegene Ltd registered volume of 5.38 lakh shares by 10:45 IST on BSE, a 38.48 fold spurt over two-week average daily volume of 13975 shares. The stock slipped 0.45% to Rs.471.05. Volumes stood at 10855 shares in the last session.APL Apollo Tubes Ltd witnessed volume of 14.11 lakh shares by 10:45 IST on BSE, a 18.13 times surge over two-week average daily volume of 77831 shares. The stock dropped 0.04% to Rs.2,279.70. Volumes stood at 80089 shares in the last session.Elgi Equipments Ltd notched up volume of 7.69 lakh shares by 10:45 IST on BSE, a 14.42 fold spurt over two-week average daily volume of 53332 shares. The stock rose 4.03% to Rs.516.50. Volumes stood at 18752 shares in the last session.Kirloskar Oil Engines Ltd clocked volume of 1.87 lakh shares by 10:45 IST on BSE, a 9.43 times surge over two-week average daily volume of 19797 shares. The stock gained 5.25% to Rs.1,392.10. Volumes stood at 48933 shares in the last session.AAVAS Financiers Ltd clocked volume of 99417 shares by 10:45 IST on BSE, a 8.94 times surge over two-week average daily volume of 11115 shares. The stock gained 0.79% to Rs.1,318.60. Volumes stood at 7842 shares in the last session.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Indegene consolidated net profit declines 6.20% in the December 2025 quarter
Net profit of Indegene declined 6.20% to Rs 102.90 crore in the quarter ended December 2025 as against Rs 109.70 crore during the previous quarter ended December 2024. Sales rose 30.77% to Rs 942.10 crore in the quarter ended December 2025 as against Rs 720.40 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales942.10720.40 31 OPM %16.9318.30 - PBDT174.30166.30 5 PBT134.70146.30 -8 NP102.90109.70 -6 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Indegene appoints Jill DeSimone and Neeraj Bharadwaj to its board
Indegene today announced that Jill DeSimone, a widely respected global life sciences leader, and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene's Board of Directors. Jill brings over four decades of life sciences leadership, with hands-on experience building and leading large commercial and medical organizations. She has held senior leadership roles at leading biopharma companies, including President of U.S. Oncology at Merck, where she led major businesses and product franchises across global markets. She led the launch of Keytruda, Merck's first true oncology product. Jill has also held leadership roles at Teva and Bristol Myers Squibb. She currently serves on the Boards of several public and private biotech companies and brings a valuable set of experiences to Indegene. Neeraj brings extensive experience in private equity, capital allocation, and portfolio value creation. He is currently a Senior Advisor with Carlyle Asia and previously held leadership roles at Accel Partners' growth investing operations in India and Apax Partners. He has worked closely with boards and management teams to support disciplined growth, inorganic expansion, and sustained value creation across scaled businesses, including healthcare and technology-enabled services.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Indegene to convene board meeting
Indegene will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Indegene to acquire Trilogy Writing & Consulting Inc.
Indegene announced that the company's wholly owned subsidiaries, Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH have, on 31 December 2025, signed a Share Purchase Agreement (SPA) to acquire 100% equity shares in Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)) (Trilogy Canada) (Target Company), wholly owned subsidiary of Trilogy Writing and Consulting GmbH. Consequent to the above Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada) will cease to be the subsidiary of Trilogy Writing and Consulting GmbH and become the wholly owned subsidiary of Indegene, Inc. Trilogy Canada specialises in medical writing. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Indegene consolidated net profit rises 11.34% in the September 2025 quarter
Net profit of Indegene rose 11.34% to Rs 102.10 crore in the quarter ended September 2025 as against Rs 91.70 crore during the previous quarter ended September 2024. Sales rose 17.09% to Rs 804.20 crore in the quarter ended September 2025 as against Rs 686.80 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales804.20686.80 17 OPM %17.4818.36 - PBDT156.50143.50 9 PBT133.10124.10 7 NP102.1091.70 11 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Indegene to conduct board meeting
Indegene will hold a meeting of the Board of Directors of the Company on 30 October 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 35.42%, vs industry avg of 11.25%
Over the last 5 years, market share increased from 3.67% to 7.94%